CLINICAL_TRIALS trial_result · 2025-05-16

Clinical Trial Update: Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL [Phase 2]

A Phase 2 study evaluating huCART19 for very high-risk pediatric B-cell acute lymphoblastic leukemia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: University of Pennsylvania | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2025-05-16